FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W56968070> ?p ?o ?g. }

• W56968070 endingPage "933" @default.
• W56968070 startingPage "923" @default.
• W56968070 abstract "The aim of this study was to assess the safety and effectiveness of directional atherectomy (DA) for endovascular treatment of peripheral arterial disease (PAD) in infrainguinal arteries in patients with claudication or critical limb ischemia.To date, no prospective, multicenter, independently-adjudicated study has evaluated the effectiveness and durability of DA in the treatment of PAD. Previous DA studies have not been prospectively powered to evaluate any differences in outcomes in patients with and without diabetes.DEFINITIVE LE (Determination of EFfectiveness of the SilverHawk(®) PerIpheral Plaque ExcisioN System (SIlverHawk Device) for the Treatment of Infrainguinal VEssels / Lower Extremities) prospectively enrolled subjects at 47 multinational centers with an infrainguinal lesion length up to 20 cm. Primary endpoints were defined as primary patency at 12 months for claudicants and freedom from major unplanned amputation for critical limb ischemia (CLI) subjects. A pre-specified statistical hypothesis evaluated noninferiority of primary patency in diabetic versus nondiabetic claudicants. Independent angiographic and sonographic core laboratories assessed outcomes, and events were adjudicated by a clinical events committee.A total of 800 subjects were enrolled. The 12-month primary patency was 78% (95% confidence interval: 74.0% to 80.6%) in claudicants, with a 77% rate in the diabetic subgroup versus 78% in the nondiabetic subgroup (noninferior, p < 0.001). The rate of freedom from major unplanned amputation of the target limb at 12 months in CLI subjects was 95% (95% confidence interval: 90.7% to 97.4%). Periprocedural adverse events included embolization (3.8%), perforation (5.3%), and abrupt closure (2.0%). The bail-out stent rate was 3.2%.The DEFINITIVE LE study demonstrated that DA is a safe and effective treatment modality at 12 months for a diverse patient population with either claudication or CLI. Furthermore, DA was shown to be noninferior for treating PAD in patients with diabetes compared with those without diabetes. (Study of SilverHawk/TurboHawk in Lower Extremity Vessels [DEFINITIVE LE]; NCT00883246)." @default.
• W56968070 created "2016-06-24" @default.
• W56968070 creator A5036329954 @default.
• W56968070 creator A5047252742 @default.
• W56968070 creator A5065985671 @default.
• W56968070 creator A5069076517 @default.
• W56968070 creator A5089616237 @default.
• W56968070 creator A5089671475 @default.
• W56968070 date "2014-08-01" @default.
• W56968070 modified "2023-10-01" @default.
• W56968070 title "Lower Extremity Revascularization Using Directional Atherectomy" @default.
• W56968070 cites W122961614 @default.
• W56968070 cites W1561264208 @default.
• W56968070 cites W1969838166 @default.
• W56968070 cites W1971601137 @default.
• W56968070 cites W1975134053 @default.
• W56968070 cites W1976985351 @default.
• W56968070 cites W1982187283 @default.
• W56968070 cites W1982669079 @default.
• W56968070 cites W1984690909 @default.
• W56968070 cites W1988902767 @default.
• W56968070 cites W2008850799 @default.
• W56968070 cites W2026190702 @default.
• W56968070 cites W2029653225 @default.
• W56968070 cites W2034616812 @default.
• W56968070 cites W2049813945 @default.
• W56968070 cites W2079069762 @default.
• W56968070 cites W2099225 @default.
• W56968070 cites W2110101054 @default.
• W56968070 cites W2111054174 @default.
• W56968070 cites W2119220858 @default.
• W56968070 cites W2131596842 @default.
• W56968070 cites W2132880199 @default.
• W56968070 cites W2140136269 @default.
• W56968070 cites W2140375787 @default.
• W56968070 cites W2156978259 @default.
• W56968070 cites W2164007934 @default.
• W56968070 cites W2165208882 @default.
• W56968070 cites W2168393911 @default.
• W56968070 cites W2171923126 @default.
• W56968070 cites W2185467918 @default.
• W56968070 cites W2887033821 @default.
• W56968070 cites W2887208783 @default.
• W56968070 cites W39174031 @default.
• W56968070 cites W4210953420 @default.
• W56968070 doi "https://doi.org/10.1016/j.jcin.2014.05.006" @default.
• W56968070 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25147039" @default.
• W56968070 hasPublicationYear "2014" @default.
• W56968070 type Work @default.
• W56968070 sameAs 56968070 @default.
• W56968070 citedByCount "204" @default.
• W56968070 countsByYear W569680702014 @default.
• W56968070 countsByYear W569680702015 @default.
• W56968070 countsByYear W569680702016 @default.
• W56968070 countsByYear W569680702017 @default.
• W56968070 countsByYear W569680702018 @default.
• W56968070 countsByYear W569680702019 @default.
• W56968070 countsByYear W569680702020 @default.
• W56968070 countsByYear W569680702021 @default.
• W56968070 countsByYear W569680702022 @default.
• W56968070 countsByYear W569680702023 @default.
• W56968070 crossrefType "journal-article" @default.
• W56968070 hasAuthorship W56968070A5036329954 @default.
• W56968070 hasAuthorship W56968070A5047252742 @default.
• W56968070 hasAuthorship W56968070A5065985671 @default.
• W56968070 hasAuthorship W56968070A5069076517 @default.
• W56968070 hasAuthorship W56968070A5089616237 @default.
• W56968070 hasAuthorship W56968070A5089671475 @default.
• W56968070 hasBestOaLocation W569680701 @default.
• W56968070 hasConcept C126322002 @default.
• W56968070 hasConcept C141071460 @default.
• W56968070 hasConcept C168563851 @default.
• W56968070 hasConcept C188816634 @default.
• W56968070 hasConcept C203092338 @default.
• W56968070 hasConcept C2776204877 @default.
• W56968070 hasConcept C2777466421 @default.
• W56968070 hasConcept C2778963770 @default.
• W56968070 hasConcept C2779464278 @default.
• W56968070 hasConcept C2781099653 @default.
• W56968070 hasConcept C3018348675 @default.
• W56968070 hasConcept C44249647 @default.
• W56968070 hasConcept C500558357 @default.
• W56968070 hasConcept C71924100 @default.
• W56968070 hasConceptScore W56968070C126322002 @default.
• W56968070 hasConceptScore W56968070C141071460 @default.
• W56968070 hasConceptScore W56968070C168563851 @default.
• W56968070 hasConceptScore W56968070C188816634 @default.
• W56968070 hasConceptScore W56968070C203092338 @default.
• W56968070 hasConceptScore W56968070C2776204877 @default.
• W56968070 hasConceptScore W56968070C2777466421 @default.
• W56968070 hasConceptScore W56968070C2778963770 @default.
• W56968070 hasConceptScore W56968070C2779464278 @default.
• W56968070 hasConceptScore W56968070C2781099653 @default.
• W56968070 hasConceptScore W56968070C3018348675 @default.
• W56968070 hasConceptScore W56968070C44249647 @default.
• W56968070 hasConceptScore W56968070C500558357 @default.
• W56968070 hasConceptScore W56968070C71924100 @default.
• W56968070 hasFunder F4320321443 @default.

• next